Yearly Archives: 2026
Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
U.S. Representative Celeste Maloy (R-UT) on Aug. 19 toured the Biologic Input Output Systems (BIOS) lab, part of the University of Utah’s Craig H. Neilsen Rehabilitation Hospital, to observe research into prosthetics innovation. Led by University of Utah NeuroRobotics Lab Director and BIOS Chief Scientist Jacob “Jake” George, alongside BIOS Chief Development Officer Tim Miller, […]
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation
Sera Prognostics Appoints Scott Gleason CFO
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 […]
Merit Medical Announces Global Operations Leadership Transition
Sheri Lewis has agreed to join Merit as Executive VP of Global Operations, effective August 31.
Utah Life Sciences Innovation Caucus Breakfast
Utah lawmakers on Aug, 19 attended a breakfast meeting of the Utah Life Sciences Innovation Caucus (ULSIC).
Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors
Combined operations deliver unified trial delivery, faster recruitment, and expanded evidence-generation capabilities.
Sethera Therapeutics’ Polymacrocyclic Peptide Platform Selected for CDMRP-Supported Mutant p53 Breast Cancer Program
The award supports innovative, high-impact research aimed at advancing the prevention, diagnosis, and treatment of breast cancer.
Clene Announces Biomarker Analyses To Be Included in NDA Submission Supporting ALS Accelerated Approval
Survival benefit is concentrated in participants with NfL biomarker response.
CancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer
In-vitro studies confirmed revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells.
Teledyne to Acquire Varex Imaging Corporation
Teledyne will acquire all of the outstanding common shares of Varex for $18.90 per share, payable in cash.
BYU and BioUtah Connect Utah’s Life Sciences Industry at Annual Networking Lunch
BioUtah and BYU’s College of Life Sciences hosted the annual BYU/BioUtah Networking Lunch on August 7 at BYU’s Life Sciences Building in Provo. Nearly 100 people attended out of more than 100 registrants, bringing together life sciences companies from across the state with BYU’s research and tech transfer community. The lunch is one piece of […]
Strategic Transactions Advocacy Track (STAT)
STAT delivers U.S. Government Advocacy for Foreign Investment & Concession Projects
